Tanshinone IIA attenuates AOM/DSS-induced colorectal tumorigenesis in mice via inhibition of intestinal inflammation

References

• An G, Wei B, Xia B, McDaniel JM, Ju T, Cummings RD, Braun J, Xia L. 2007. Increased susceptibility to colitis and colorectal tumors in mice lacking core 3-derived O-glycans. J Exp Med. 204(6):1417–1429.
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Svrcek M, Seksik P, Bouvier AM, Simon T, Allez M, Brixi H, Gornet JM, Altwegg R, Beau P, et al. 2013. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 145(1):166–175.e8.
   PubMed Web of Science ®Google Scholar
• Becker J, Ott D, Diener M. 2019. Impact of sensitization and inflammation on the interaction of mast cells with the intestinal epithelium in rats. Front Physiol. 10:1–14.
   PubMed Web of Science ®Google Scholar
• Deng S, Wang A, Chen X, Du Q, Wu Y, Chen G, Guo W, Li Y. 2019. HBD inhibits the development of colitis-associated cancer in mice via the IL-6R/STAT3 signaling pathway. IJMS. 20(5):1069.
   Google Scholar
• Dong Y, Morris-Natschke SL, Lee KH. 2011. Biosynthesis, total syntheses, and antitumor activity of tanshinones and their analogs as potential therapeutic agents. Nat Prod Rep. 28(3):529–542.
   PubMed Web of Science ®Google Scholar
• Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, Diaz LA. 2019. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 16(6):361–375.
   PubMed Web of Science ®Google Scholar
• Gao F, Li M, Liu W, Li W. 2020. Inhibition of EGFR signaling and activation of mitochondrial apoptosis contribute to tanshinone IIA-mediated tumor suppression in non-small cell lung cancer cells. Onco Targets Ther. 13:2757–2769.
   PubMed Web of Science ®Google Scholar
• Gao S, Liu Z, Li H, Little PJ, Liu P, Xu S. 2012. Cardiovascular actions and therapeutic potential of tanshinone IIA. Atherosclerosis. 220(1):3–10.
   PubMed Web of Science ®Google Scholar
• Hull MA, Faluyi OO, Ko CWS, Holwell S, Scott DJ, Cuthbert RJ, Poulsom R, Goodlad R, Bonifer C, Markham AF, et al. 2006. Regulation of stromal cell cyclooxygenase-2 in the ApcMin/+ mouse model of intestinal tumorigenesis. Carcinogenesis. 27(3):382–391.
   PubMed Web of Science ®Google Scholar
• Ji B, Zhou F, Han L, Yang J, Fan H, Li S, Li J, Zhang X, Wang X, Chen X, et al. 2017. Sodium tanshinone IIA sulfonate enhances effectiveness Rt-PA treatment in acute ischemic stroke patients associated with ameliorating blood-brain barrier damage. Transl Stroke Res. 8(4):334–340.
   PubMed Web of Science ®Google Scholar
• Jiang F, Liu M, Wang H, Shi G, Chen B, Chen T, Yuan X, Zhu P, Zhou J, Wang Q, et al. 2020. Wu Mei Wan attenuates CAC by regulating gut microbiota and the NF-κB/IL6-STAT3 signaling pathway. Biomed Pharmacother. 125:109982.
   PubMed Web of Science ®Google Scholar
• Jieensinue S, Zhu H, Li G, Dong K, Liang M, Li Y. 2018. Tanshinone IIA reduces SW837 colorectal cancer cell viability via the promotion of mitochondrial fission by activating JNK-Mff signaling pathways. BMC Cell Biol. 19(1):21.
   PubMedGoogle Scholar
• Johnson CM, Wei C, Ensor JE, Smolenski DJ, Amos CI, Levin B, Berry DA. 2013. Meta-analyses of colorectal cancer risk factors. Cancer Causes Control. 24(6):1207–1222.
   PubMed Web of Science ®Google Scholar
• Li B, Wang Y, Yin L, Huang G, Xu Y, Su J, Ma L, Lu J. 2019. Glucocorticoids promote the development of azoxymethane and dextran sulfate sodium-induced colorectal carcinoma in mice. BMC Cancer. 19(1):94.
   PubMedGoogle Scholar
• Lin L, Wang D, Qu S, Zhao H, Lin Y. 2020. MiR-370-3p alleviates ulcerative colitis-related colorectal cancer in mice through inhibiting the inflammatory response and epithelial-mesenchymal transition. Drug Des Devel Ther. 14:1127–1141.
   PubMed Web of Science ®Google Scholar
• Liu X, He H, Huang T, Lei Z, Liu F, An G, Wen T. 2016. Tanshinone IIA protects against dextran sulfate sodium- (DSS-) induced colitis in mice by modulation of neutrophil infiltration and activation. Oxid Med Cell Longev. 2016:7916763.
   PubMed Web of Science ®Google Scholar
• Lutgens MWMD, van Oijen MGH, van der Heijden GJMG, Vleggaar FPV, Siersema PD, Oldenburg B. 2013. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis. 19(4):789–799.
   PubMed Web of Science ®Google Scholar
• Malgorzata KK, Dorota D, Bartosz K, Marek B, Andrzej G. 2013. Profiles of circulating inflammatory cytokines in colorectal cancer (CRC), high cancer risk conditions, and health are distinct. Possible implications for CRC screening and surveillance. Cancer Lett. 337:107–114.
   PubMed Web of Science ®Google Scholar
• Malhotra A, Phatharacharukul P, Thongprayoon C. 2018. Risk factors for 90-day readmission in veterans with inflammatory bowel disease-Does post-discharge follow-up matter? Mil Med Res. 5(1):5–11.
   PubMedGoogle Scholar
• Park JH, Kim JK. 2018. Pristimerin, a naturally occurring triterpenoid, attenuates tumorigenesis in experimental colitis-associated colon cancer. Phytomedicine. 42:164–171.
   PubMed Web of Science ®Google Scholar
• Pejin B, Iodice C, Bogdanović G, Kojić V, Tešević V. 2017. Stictic acid inhibits cell growth of human colon adenocarcinoma HT-29 cells. Arab J Chem. 10:S1240–S1242.
   Web of Science ®Google Scholar
• Pejin B, Jovanović KK, Mojović M, Savić AG. 2013. New and highly potent antitumor natural products from marine-derived fungi: covering the period from 2003 to 2012. Curr Top Med Chem. 13(21):2745–2766.
   PubMed Web of Science ®Google Scholar
• Robertson AL, Holmes GR, Bojarczuk AN, Burgon J, Loynes CA, Chimen M, Sawtell AK, Hamza B, Willson J, Walmsley SR, et al. 2014. A zebrafish compound screen reveals modulation of neutrophil reverse migration as an anti-inflammatory mechanism. Sci Transl Med. 6(225):225ra29.
   PubMed Web of Science ®Google Scholar
• Shu M, Hu X, Hung Z, Huang D, Zhang S. 2016. Effects of tanshinone IIA on fibrosis in a rat model of cirrhosis through heme oxygenase-1, inflammation, oxidative stress and apoptosis. Mol Med Rep. 13(4):3036–3042.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. 2019. Cancer statistics, 2019. CA A Cancer J Clin. 69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Soleimani A, Rahmani F, Ferns GA, Ryzhikov M, Avan A, Hassanian SM. 2020. Role of the NF-κB signaling pathway in the pathogenesis of colorectal cancer. Gene. 726:144132.
   PubMed Web of Science ®Google Scholar
• Tago K, Funakoshi-Tago M, Ohta S, Kawata H, Saitoh H, Horie H, Aoki-Ohmura C, Yamauchi J, Tanaka A, Matsugi J, et al. 2019. Oncogenic Ras mutant causes the hyperactivation of NF-κB via acceleration of its transcriptional activation. Mol Oncol. 13(11):2493–2510.
   PubMed Web of Science ®Google Scholar
• Terzić J, Grivennikov S, Karin E, Karin M. 2010. Inflammation and colon cancer. Gastroenterology. 138(6):2101–2114.e5.
   PubMed Web of Science ®Google Scholar
• Wan G, Xie M, Zhang X, Li M. 2019. Chang-wei-qing, a Chinese herbal formula, ameliorates colitis-associated tumor development via inhibiting NF-κB and STAT3 signaling pathway. Pharm Biol. 57(1):231–237.
   PubMed Web of Science ®Google Scholar
• Wang Y, Li Z, Xu S, Guo J. 2020. Novel potential tumor biomarkers: Circular RNAs and exosomal circular RNAs in gastrointestinal malignancies. J Clin Lab Anal. 34(7):e23359.
   PubMed Web of Science ®Google Scholar
• West NR, McCuaig S, Franchini F, Powrie F. 2015. Emerging cytokine networks in colorectal cancer. Nat Rev Immunol. 15(10):615–629.
   PubMed Web of Science ®Google Scholar
• Williams BB, Tebbutt NC, Buchert M, Putoczki TL, Doggett K, Bao S, Johnstone CN, Masson F, Hollande F, Burgess AW, et al. 2015. Glycoprotein A33 deficiency: a new mouse model of impaired intestinal epithelial barrier function and inflammatory disease. Dis Model Mech. 8(8):805–815.
   PubMed Web of Science ®Google Scholar
• Xing Y, Tu J, Zheng L, Guo L, Xi T. 2015. Anti-angiogenic effect of tanshinone IIA involves inhibition of the VEGF/VEGFR2 pathway in vascular endothelial cells. Oncol Rep. 33(1):163–170.
   PubMed Web of Science ®Google Scholar
• Yahyapour R, Amini P, Rezapour S, Cheki M, Rezaeyan A, Farhood B, Shabeeb D, Musa AE, Fallah H, Najafi M. 2018. Radiation-induced inflammation and autoimmune diseases. Mil Med Res. 5(1):9–17.
   PubMed Web of Science ®Google Scholar
• Yang L-J, Jeng C-J, Kung H-N, Chang C-C, Wang A-G, Chau G-Y, Don M-J, Chau Y-P. 2005. Tanshinone IIA isolated from Salvia miltiorrhiza elicits the cell death of human endothelial cells. J Biomed Sci. 12(2):347–361.
   PubMed Web of Science ®Google Scholar
• Yu LCH. 2018. Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis. J Biomed Sci. 25(1):79.
   PubMedGoogle Scholar
• Zhang X, Wang Y, Ma Z, Liang Q, Tang X, Hu D, Tan H, Xiao C, Gao Y. 2015. Tanshinone IIA ameliorates dextran sulfate sodium-induced inflammatory bowel disease via the pregnane X receptor. Drug Des Devel Ther. 9:6343–6362.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ge T, Xiang P, Zhou J, Tang S, Mao H, Tang Q. 2019. Tanshinone IIA reverses oxaliplatin resistance in human colorectal cancer via inhibition of ERK/Akt signaling pathway. Onco Targets Ther. 12:9725–9734.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Bi Y, Zhong J, Ren Z, Liu Y, Jia J, Yu M, Tan Y, Zhang Q, Yu X, et al. 2020. Pristimerin suppresses colorectal cancer through inhibiting inflammatory responses and Wnt/β-catenin signaling. Toxicol Appl Pharmacol. 386:114813.
   PubMed Web of Science ®Google Scholar
• Zhou D, Jin J, Liu Q, Shi J, Hou Y. 2019. PPARδ agonist enhances colitis-associated colorectal cancer. Eur J Pharmacol. 842:248–254.
   PubMed Web of Science ®Google Scholar